RBC Capital Believes Sarepta Therapeutics (NASDAQ: SRPT) Still Has Room to Grow

By Jason Carr

In a report issued on March 12, Brian Abrahams from RBC Capital reiterated a Buy rating on Sarepta Therapeutics (NASDAQ: SRPT), with a price target of $91. The company’s shares opened today at $82.27, close to its 52-week high of $82.77.

According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 12.5% and a 54.8% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Proteostasis Therapeutics Inc, and Achillion Pharmaceuticals.

Currently, the analyst consensus on Sarepta Therapeutics is Strong Buy and the average price target is $80.77, representing a -1.8% downside.

In a report issued on March 2, Cowen & Co. also maintained a Buy rating on the stock with a $71 price target.

Based on Sarepta Therapeutics’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $57.28 million and GAAP net loss of $24 million. In comparison, last year the company earned revenue of $5.42 million and had a GAAP net loss of $88.45 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sarepta Therapeutics, Inc. is a biopharmaceutical company, which is engaged in the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. It focuses on the development of its potentially disease-modifying DMD drug candidates.